Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by West China Second University Hospital
Sponsor:
Collaborators:
Sichuan Academy of Medical Sciences
people's hospital of Guang'an
pengzhou shi fuyou baojianyuan
The first people's hospital of Neijiang
Suining Central Hospital
Sichuan Provincial Maternal and Child Health Care Hospital
Chengdu Women's and Children's Central Hospital
Information provided by (Responsible Party):
Xinghui Liu, West China Second University Hospital
ClinicalTrials.gov Identifier:
NCT01806454
First received: March 1, 2013
Last updated: April 6, 2014
Last verified: April 2014

March 1, 2013
April 6, 2014
October 2013
May 2014   (final data collection date for primary outcome measure)
incidence of pre-eclampsia [ Time Frame: postpartum forty-two days ] [ Designated as safety issue: No ]
incidence of pre-eclampsia [ Time Frame: postpartum forty-two days ]
Complete list of historical versions of study NCT01806454 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China
Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China: a Multi-center, Prospective Random Trial

the purpose of this study is to determine whether calcium supplementation is effective to prevent preeclampsia in Sichuang Province of china and which dose is more suitable

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Preeclampsia
Drug: calcium
  • Active Comparator: calcium A
    tablets, 600mg per day,till birth
    Intervention: Drug: calcium
  • Active Comparator: calcium B
    tablets,1200mg per day,till birth
    Intervention: Drug: calcium
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
11000
Not Provided
May 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Nulliparity;age ≥35 years;Previous pre-eclampsia;Family history of pre-eclampsia;Multiple pregnancy;Time between pregnancies ≥10years;Body mass index ≥25;diastolic pressure ≥ 80 mm Hg before 20 weeks' gestation;Proteinuria ≥+ on more than one occasion or ≥ 300 mg/24 h before 20 weeks' gestation;Underlying medical conditions(Pre-existing hypertension;Pre-existing renal disease;Pre-existing diabetes;Presence of antiphospholipid antibodies;Chronic autoimmune disease);male sex partner's predecessor wife has Previous pre-eclampsia

Exclusion Criteria:

  • first prenatal visit after 16 weeks' gestation;severe anemia;other Underlying medical conditions which need treatment first (such as uncontrolled hyperthyreosis )
Female
Not Provided
No
Contact: peng chen cpyxwd007@gmail.com
China
 
NCT01806454
hx2ck1
Not Provided
Xinghui Liu, West China Second University Hospital
West China Second University Hospital
  • Sichuan Academy of Medical Sciences
  • people's hospital of Guang'an
  • pengzhou shi fuyou baojianyuan
  • The first people's hospital of Neijiang
  • Suining Central Hospital
  • Sichuan Provincial Maternal and Child Health Care Hospital
  • Chengdu Women's and Children's Central Hospital
Not Provided
West China Second University Hospital
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP